Selective blockade of TNFR1 improves clinical disease and bronchoconstriction in experimental RSV infection

Keyphrases

• Clinical Disease 100%
• TNF Receptor 1 (TNFR1) 100%
• Respiratory Syncytial Virus Infection 100%
• Bronchoconstriction 100%
• Respiratory Syncytial Virus 57%
• Tumor Necrosis Factor-α 42%
• Interleukin-1β 28%
• Tumor Necrosis Factor Receptor 2 (TNFR2) 28%
• Lung 14%
• Inflammation 14%
• Chemokines 14%
• Mouse Model 14%
• Therapeutic Approaches 14%
• Neutrophils 14%
• Potential Therapeutics 14%
• Cell Death 14%
• Interleukin-6 14%
• Inflammatory Cytokines 14%
• Major Contributor 14%
• Inflammatory Chemokines 14%
• Bronchiolitis 14%
• Young children 14%
• Neutrophil Activation 14%
• Airway Disease 14%
• Carbon Tetrachloride 14%
• Protective Behavior 14%
• CCL3 14%
• Respiratory Syncytial Virus Bronchiolitis 14%
• Alveolar Macrophages 14%
• Infant Patients 14%
• Virus Inoculation 14%
• Antibody-mediated 14%
• CCL5 14%
• CXCL1 14%
• Macrophage Survival 14%
• CXCL2 14%
• Activation Status 14%

Immunology and Microbiology

• Human Respiratory Syncytial Virus 100%
• Respiratory Syncytial Virus Infection 100%
• Tumor Necrosis Factor Alpha 60%
• Chemokine 40%
• Reduction (Chemistry) 40%
• Bronchiolitis 40%
• Interleukin-1 40%
• Monospecific Antibody 20%
• Mouse 20%
• Inflammation 20%
• Lung 20%
• Mouse Model 20%
• Neutrophil Granulocyte 20%
• Dose 20%
• Cell Death 20%
• Interleukin-6 20%
• Inflammatory Cytokine 20%
• Survival 20%
• Bagg Albino Mouse 20%
• Alveolar Macrophage 20%
• Leukocyte Activation 20%
• Tumor Necrosis Factor Receptor 1 20%

INIS

• diseases 100%
• viruses 100%
• tumor necrosis factor 57%
• receptors 42%
• mice 28%
• inflammation 28%
• reduction 28%
• neutrophils 28%
• antibodies 14%
• children 14%
• doses 14%
• apoptosis 14%
• cytokines 14%
• lungs 14%
• macrophages 14%
• infants 14%
• peaks 14%
• inoculation 14%
• carbon tetrachloride 14%